OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kahl on the Evolving Role of BTK Inhibitors in MCL

June 27th 2025

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

Dr Halmos on Differentiating Neuroendocrine Tumors From Neuroendocrine Carcinomas

June 27th 2025

Balazs Halmos, MD, discusses the differences in presentation and available treatments between neuroendocrine tumors and neuroendocrine carcinomas.

Dr Randall on the Evolving Role of Surgical Management in Low-Grade Chondrosarcoma

June 27th 2025

R. Lor Randall, MD, FACS discusses the evolving role of surgical management in patients with low-grade chondrosarcoma.

Dr Nagasaka on the Importance of Taletrectinib for the ROS1+ NSCLC Treatment Paradigm

June 27th 2025

Misako Nagasaka, MD, PhD, discussed the clinical significance of the FDA approval of taletrectinib in ROS1-positive NSCLC.

Dr Palandri on Outcomes With Momelotinib in Myelofibrosis Per Dual SVR35 and Transfusion Independence

June 27th 2025

Francesca Palandri, MD, shares SVR35 rates with momelotinib vs ruxolitinib across patient subgroups in the anemic subpopulation of SIMPLIFY-1.

Dr Reni on the Efficacy of Preoperative PAXG in Stage I to III PDAC

June 26th 2025

Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.

Dr Johnson on Treatment Gaps With Immunotherapy in Melanoma

June 25th 2025

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Dr Moser on the SUPRAME Trial of IMA203 in Pretreated Cutaneous Melanoma

June 25th 2025

Justin Moser, MD, discusses the design and implications of the SUPRAME trial investigating IMA203 in pretreated advanced cutaneous melanoma.

Dr Isaacs on Establishing Consensus on DESTINY-Breast09 Data in HER2+ Metastatic Breast Cancer

June 25th 2025

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Dr McCann on the Importance of Reaching Consensus on the Role of Vepdegestrant in ER+ Breast Cancer

June 25th 2025

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.

Dr Olawaiye on Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 25th 2025

Alexander B. Olawaiye, MD, discusses clinical implications of data from the phase 3 ROSELLA trial.

Dr Stein on the Emerging Role of Menin Inhibitors in Frontline Combinations for AML

June 25th 2025

Eytan M. Stein, MD, discusses the emerging role of menin inhibitors such as revumenib in combination treatment strategies for AML.

Dr Kuykendall on the Rationale for Targeting the Hepcidin Pathway With Rusfertide in Polycythemia Vera

June 24th 2025

Andrew Kuykendall, MD, discusses the rationale for using rusfertide to target the hepcidin pathway in patients with polycythemia vera.

Dr Vose on the Durability of Response to Epcoritamab Monotherapy in DLBCL

June 24th 2025

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Dr McArthur on the Expanding Clinical Impact of ADCs in HER2+ Breast Cancer

June 24th 2025

Heather McArthur, MD, MPH, discusses the expanding clinical impact of ADCs in HER2-positive breast cancer.

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

June 24th 2025

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Dr Janjigian on the Efficacy of Durvalumab Plus Chemotherapy in Resectable GEJ Adenocarcinoma

June 24th 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Dr Halmos on the FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLC

June 23rd 2025

Balazs Halmos, MD, MS, discusses the FDA’s accelerated approval of datopotamab deruxtecan for EGFR-mutated NSCLC.

Dr Mascarenhas on the Efficacy of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

June 23rd 2025

John O. Mascarenhas, MD, discussed findings from the IMproveMF trial investigating imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Dr Fankuchen on Practice-Informing Updates to the Thoracic Oncology Treatment Paradigm

June 23rd 2025

Olivia Fankuchen, MD, MS, highlights molecular targets, trial data, and real-world experiences that have immediate implications for the lung cancer field.